

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Gębicki <i>et al.</i> Appl. No.: 10/585,892 35 U.S.C. § 371 Date: July 11, 2006 U.S. Nat'l Stage of PCT/EP05/50057; I.A. Fd: January 7, 2005 For: Use of Quaternary Pyridinium Salts as Vasoprotective Agents	Confirmation No.: 7625 Art Unit: 1614 Examiner: Nelson Clarence Blakely III Atty. Docket: 2782.0010000/MAC
--	---

Third Supplemental Information Disclosure Statement

under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Madam Commissioner:

Listed on accompanying IDS Form PTO/SB/08A are documents that may be considered material to the patentability of this application as defined in 37 C.F.R. § 1.56, and in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.97 and 1.98. Copies of U.S. patents and patent application publications are not submitted in accordance with the U.S. Patent and Trademark Office OG notice of October 19, 2004, which states: "the requirement in 37 C.F.R. § 1.98(a)(2)(iii) for a legible copy of the specification, including the claims, and drawings of each cited pending U.S. patent application (or portion of the application which caused it to be listed) is *sua sponte* waived where the cited pending application is stored in the USPTO's IFW system."

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is

not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated. Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required. It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala

Michele A. Cimbala
Attorney for Applicants
Registration No. 33,851

Date: February 27, 2009

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600

923529_1.DOC